- RecruitingPHASE3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
This study is testing a new drug, AZD2265, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see if AZD2265 works better than current treatments at slowing down cancer growth and helping men live longer.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Austria - Active not recruitingPHASE3
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
This study looks at a new drug, apalutamide, alongside standard radiation for high-risk prostate cancer. Researchers want to see if this combination improves how long patients live without the cancer spreading, compared to usual treatments.
For: Prostatic NeoplasmsUnited States · Argentina · Belgium - RecruitingPHASE1, PHASE2
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
This study is looking into a new combination of medicines, SX-682 and Apalutamide, for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see if this new combination can help slow down the cancer.
For: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)Switzerland · United Kingdom - Active not recruiting
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
This study looks at real-world results for men with prostate cancer that has spread and is sensitive to hormones. It compares two medicines, apalutamide and enzalutamide, which are given alongside standard hormone therapy to see how well they work.
For: Metastatic Hormone-sensitive Prostate CancerAustria · France · Germany - Active not recruitingPHASE3
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study is looking at a new combination of medicines for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It aims to see if adding a drug called apalutamide to current treatment helps men live longer without their cancer getting worse.
For: Prostatic NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
This study looks at adding a new drug, Apalutamide, to standard hormone therapy for men with prostate cancer that has spread. We want to see if this combination helps patients live longer or keeps their cancer from getting worse.
For: Prostate CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
This study looks at a new drug, apalutamide, combined with standard hormone therapy for men with high-risk prostate cancer before and after surgery. It aims to see if this combination helps shrink the cancer more and prevents it from spreading, compared to hormone therapy alone.
For: Prostatic NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, apalutamide, for men with prostate cancer that hasn't spread but is resistant to standard treatment. It aims to see if the drug can stop the cancer from spreading and if it's safe to use.
For: Prostatic NeoplasmsUnited States · Australia · Austria - RecruitingPHASE1
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
This study looks at new drug combinations for advanced prostate cancer. Researchers want to find the safest and most effective doses of new medicines and see how well they work together, sometimes with existing treatments, to help men with this type of cancer.
For: Prostatic NeoplasmsUnited States · France · Japan - Active not recruitingPHASE3
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
This study is looking at whether adding a drug called apalutamide to standard prostate cancer treatments (radiotherapy and hormone therapy) helps men with high-risk prostate cancer live longer without their cancer spreading. It compares the new combination to the standard treatment alone.
For: Prostatic NeoplasmsUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
This study is looking at a new drug, AZD5305, combined with existing hormone therapies for men with prostate cancer that has spread. It aims to see if the combination is safe, how the body handles it, and if it helps treat the cancer.
For: Metastatic Prostate CancerUnited States · Australia · Italy - RecruitingPhase III
A study comparing the effect of apalutamide treatment before focal therapy with focal therapy alone in men with prostate cancer that has not spread beyond the prostate
This study looks at treating prostate cancer that is still within the prostate. We're comparing focal therapy alone with focal therapy after a short course of a drug called apalutamide. We want to see if using apalutamide first can make the focal therapy work even better.
For: Localised prostate cancerUnited Kingdom · England